UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Comorbidities that impact management of osteoarthritis

Authors
Karine Louati, MD
Francis Berenbaum, MD, PhD
Section Editor
David Hunter, MD, PhD
Deputy Editor
Monica Ramirez Curtis, MD, MPH

INTRODUCTION

Osteoarthritis (OA) is the most common form of arthritis and can often be disabling in adults. Although many drugs are available for the symptomatic treatment of OA, the presence of comorbidities complicates management and remains a practical challenge. Both nonpharmacologic and pharmacologic interventions may require adaptation depending on the comorbidity.

This topic will review the management of OA in patients with common comorbidities. The pathogenesis and risk factors, diagnosis, clinical manifestations, and treatment of OA are presented separately. (See "Pathogenesis of osteoarthritis" and "Risk factors for and possible causes of osteoarthritis" and "Clinical manifestations and diagnosis of osteoarthritis" and "Overview of the management of osteoarthritis" and "Management of knee osteoarthritis" and "Management of moderate to severe knee osteoarthritis".)

BACKGROUND

The prevalence of comorbidities among patients with osteoarthritis (OA) is high. In a retrospective cohort study in Canada with 207,610 patients over 30 years old, 67 percent of those with OA had at least one comorbidity which included hypertension (prevalence ratio [PR] 1.17, 95% CI 1.15-1.19), depression (PR 1.26, 95% CI 1.22-1.30), chronic obstructive pulmonary disease (COPD) (PR 1.16, 95% CI 1.11-1.21), and epilepsy (PR 1.27, 95% CI 1.13-1.13), even after adjustment for age and sex [1]. There were insufficient data to calculate the prevalence of obesity and smoking, which were more commonly recorded among patients with OA than among those without. Diabetes is also a relatively common comorbidity among OA patients, with estimates of prevalence of approximately 15 percent [2]. Other studies have shown that the metabolic syndrome is more frequent in OA patients compared with controls [3,4].

The prevalence of cardiovascular disease (CVD) among patients with OA is also high. A meta-analysis including over 32,000,000 OA patients found that they were twice as likely to have CVD [5]. Several studies have also suggested that OA is associated with excess mortality risk due to CVD, diabetes mellitus (DM), obesity, cognitive disorders, and disability [6,7] (see "Overview of the management of osteoarthritis", section on 'Mortality'). In addition, pain secondary to OA may promote hypertension, obesity, and CVD by decreasing mobility (sometimes called the “sitting disease”).

MANAGEMENT CONSIDERATIONS FOR COMORBIDITIES

The presence of comorbidities in patients with osteoarthritis (OA) often impacts treatment choices, particularly with respect to pharmacologic therapy. Among these agents, the use of oral nonsteroidal antiinflammatory drugs (NSAIDs) is often limited due to the increased risk of adverse effects in patients with common comorbidities. Otherwise, the same general management principles of OA should apply, in that all patients should also engage in nonpharmacologic measures such as weight management and exercise, braces, walking aids, and psychological interventions as appropriate. It is worth noting that the beneficial effects of exercise and weight loss are not only limited to OA but are also advantageous for several other comorbidities.

          
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Apr 14, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Birtwhistle R, Morkem R, Peat G, et al. Prevalence and management of osteoarthritis in primary care: an epidemiologic cohort study from the Canadian Primary Care Sentinel Surveillance Network. CMAJ Open 2015; 3:E270.
  2. Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open 2015; 1:e000077.
  3. Calvet J, Orellana C, Larrosa M, et al. High prevalence of cardiovascular co-morbidities in patients with symptomatic knee or hand osteoarthritis. Scand J Rheumatol 2015; :1.
  4. Visser AW, de Mutsert R, le Cessie S, et al. The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study. Ann Rheum Dis 2015; 74:1842.
  5. Hall AJ, Stubbs B, Mamas MA, et al. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23:938.
  6. Nüesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011; 342:d1165.
  7. Hawker GA, Croxford R, Bierman AS, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PLoS One 2014; 9:e91286.
  8. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22:363.
  9. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64:465.
  10. Bruyère O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016; 45:S3.
  11. Palma Dos Reis R, Giacovelli G, Girolami F, et al. Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials. Open Rheumatol J 2011; 5:69.
  12. Stepan JG, London DA, Boyer MI, Calfee RP. Blood glucose levels in diabetic patients following corticosteroid injections into the hand and wrist. J Hand Surg Am 2014; 39:706.
  13. Catalano LW 3rd, Glickel SZ, Barron OA, et al. Effect of local corticosteroid injection of the hand and wrist on blood glucose in patients with diabetes mellitus. Orthopedics 2012; 35:e1754.
  14. Kalafutova S, Juraskova B, Vlcek J. The impact of combinations of non-steroidal anti-inflammatory drugs and anti-hypertensive agents on blood pressure. Adv Clin Exp Med 2014; 23:993.
  15. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121:289.
  16. Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002; 162:2204.
  17. Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016; 45:S22.
  18. Hunter DJ. Viscosupplementation for osteoarthritis of the knee. N Engl J Med 2015; 372:1040.
  19. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2005; :CD005321.
  20. McGarry JG, Daruwalla ZJ. The efficacy, accuracy and complications of corticosteroid injections of the knee joint. Knee Surg Sports Traumatol Arthrosc 2011; 19:1649.
  21. Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011; 78:23.
  22. Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. J Rheumatol 2005; 32:1691.
  23. Roberts E, Delgado Nunes V, Buckner S, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016; 75:552.
  24. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113:1578.
  25. Glasser SP, Khodneva Y. Should acetaminophen be added to the list of anti-inflammatory agents that are associated with cardiovascular events? Hypertension 2015; 65:991.
  26. Fulton RL, Walters MR, Morton R, et al. Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort. Hypertension 2015; 65:1008.
  27. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162:276.
  28. Yusuf E, Nelissen RG, Ioan-Facsinay A, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis 2010; 69:761.
  29. Zambon S, Siviero P, Denkinger M, et al. Role of Osteoarthritis, Comorbidity, and Pain in Determining Functional Limitations in Older Populations: European Project on Osteoarthritis. Arthritis Care Res (Hoboken) 2016; 68:801.
  30. Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 2013; 310:1263.
  31. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2007; 66:433.
  32. Teichtahl AJ, Wluka AE, Tanamas SK, et al. Weight change and change in tibial cartilage volume and symptoms in obese adults. Ann Rheum Dis 2015; 74:1024.
  33. O'Neil CK, Hanlon JT, Marcum ZA. Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother 2012; 10:331.
  34. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010; 170:1979.